Accurate quantification of regional liver function is needed, and PET of specific hepatic metabolic pathways offers a unique method for this purpose. Here, we quantify hepatic galactose elimination in humans using PET and the galactose analog 2-18 F-fluoro-2-deoxy-D-galactose ( 18 F-FDGal) as the PET tracer. Methods: Eight healthy human subjects underwent 18 F-FDGal PET/CT of the liver with and without a simultaneous infusion of galactose. Hepatic systemic clearance of 18 F-FDGal was determined from linear representation of the PET data. Hepatic galactose removal kinetics were determined using measurements of hepatic blood flow and arterial and liver vein galactose concentrations at increasing galactose infusions. The hepatic removal kinetics of 18 F-FDGal and galactose and the lumped constant (LC) were determined. Results: The mean hepatic systemic clearance of 18 F-FDGal was significantly higher in the absence than in the presence of galactose (0.274 6 0.001 vs. 0.019 6 0.001 L blood/min/L liver tissue; P , 0.01), showing competitive substrate inhibition of galactokinase. The LC was 0.13 6 0.01, and the 18 F-FDGal PET with galactose infusion provided an accurate measure of the local maximum removal rate of galactose (V max ) in liver tissue compared with the V max estimated from arterio-liver venous (A-V) differences (1.41 6 0.24 vs. 1.76 6 0.08 mmol/min/L liver tissue; P 5 0.60). The first-order hepatic systemic clearance of 18 F-FDGal was enzyme-determined and can thus be used as an indirect estimate of galactokinase capacity without the need for galactose infusion or knowledge of the LC. Conclusion: 18 F-FDGal PET/CT provides an accurate in vivo measurement of human galactose metabolism, which enables the quantification of regional hepatic metabolic function.
An accurate method for preoperative quantification of regional hepatic function is important to accurately predict the postoperative remnant liver function after, for example, resection of liver tumors. Methods for estimating different hepatic metabolic functions by SPECT have been published (1, 2) , but compared with PET, SPECT suffers from low spatial and temporal resolution.
We recently developed a PET method in pigs that enables the quantification of regional hepatic removal rates of galactose using the galactose analog 2-18 F-fluoro-2-deoxy-D-galactose ( 18 F-FDGal) (3), with good reproducibility (4) . Galactose is almost exclusively metabolized in the liver, and the elimination rate of galactose from blood depends on the hepatic amount of the enzyme galactokinase, which phosphorylates galactose (5) . The maximum hepatic removal rate of galactose can be estimated for the whole liver by the galactose elimination capacity test (5) , which provides prognostic information on the survival probability of patients with acute liver failure (6) , patients with cirrhosis (7, 8) , and patients undergoing hepatic resection (9) . Therefore, we believe that the 18 F-FDGal PET/CT method is a promising tool for the quantification of regional hepatic galactose metabolism in humans and that the method is likely to have significant clinical potential.
In the present study, we quantified the hepatic 18 F-FDGal kinetics in the human liver by performing 2 dynamic 18 FFDGal PET/CT studies in 8 healthy subjects. One of the PET/CT studies was performed with a simultaneous intravenous infusion of galactose, and the other PET/CT study was performed without a galactose infusion. In pigs, galactokinase has significantly different affinities for galactose and 18 F-FDGal, which rendered it necessary to apply a lumped constant (LC) of 0.14 to the measured 18 F-FDGal kinetics for conversion to parameters of galactose kinetics (3) . Because a similar substrate specificity has been reported for human galactokinase in vitro (10, 11) , we also determined the LC for 18 F-FDGal in the human liver in the present study. The overall aim of the study was to validate the 18 F-FDGal PET/CT method for the quantification of regional hepatic galactose metabolism in humans.
MATERIALS AND METHODS

Human Subjects
Eight healthy human subjects with no history of liver disease were included. The subjects had responded to an advertisement in a local newspaper, and they were instructed not to take any food or drugs for 8 h before the studies, but they were free to drink water. They were also instructed not to consume alcohol for at least 24 h before the study. The subjects' sex, age, and body weight are shown in ½Table 1 [19] [20] [21] [22] [23] [24] [25] and normal galactose elimination capacity tests.
The study was approved by the Central Denmark Region Committees on Biomedical Research Ethics and conducted in accordance with the Helsinki II Declaration. Written informed consent was obtained from each subject. The mean radiation dose received by each subject was 7 mSv, and no complications associated with the procedures were observed.
Study Design
The subjects underwent 2 dynamic 18 F-FDGal PET/CT studies on separate days. One PET/CT study was performed with and the other PET/CT study was performed without a simultaneous intravenous infusion of galactose. The radioactive half-life of 18 F (110 min) prevented more than one 18 F-FDGal study in the same subject per day. Hepatic galactose elimination kinetics were determined by measuring the hepatic removal rates of galactose at 6 increasing levels of blood galactose. This part of the study was performed after the PET study without galactose infusion, and the hepatic blood flow was measured throughout this study day.
Liver Vein Catheterization
For the PET study without galactose infusion and the subsequent determination of hepatic galactose kinetics, a liver vein catheter (5-French catheter; Cook) was placed via an introducer catheter in the right femoral vein for liver blood sampling; the position of the catheter within the liver was verified before, during, and after the study by fluoroscopy using 5-15 mL of contrast agent (Omnipague, 240 mg/mL; GE Healthcare).
Hepatic Blood Flow
Hepatic blood flow was determined by a constant intravenous infusion of indocyanine green (Hyson, Wescott and Dunning) (12) . Sixteen pairs of blood samples were collected from a catheter placed in a radial artery (Artflon; Becton Dickinson) and the liver vein for the determination of plasma indocyanine green concentrations during the PET study without galactose infusion and the subsequent determination of galactose kinetics. No systematic variations during the day were observed, and the mean concentrations from the artery and liver vein were used to calculate a mean hepatic blood flow (F, L blood/min) for each subject according to the Fick principle and corrected for measured hematocrit (12) .
Hepatic 18 F-FDGal Kinetics
For both of the 18 F-FDGal PET/CT studies, the subjects were placed on their backs in a 40-slice Biograph TruePoint PET/CT camera (Siemens AG). A topogram of the abdomen was used for optimal positioning of the liver within the 21-cm transaxial field of view of the PET camera. A low-dose CT scan (50 effective mAs with CAREDose4D; 120 kV; pitch, 0.8; slice thickness, 5 mm) was obtained to define anatomic structures and attenuation correction of the PET data. A bolus of 100 MBq of 18 F-FDGal (range, 96-104 MBq; radiochemical purity, 98% 6 1%) (13) in 10 mL of saline was administered at the beginning of a 60-min dynamic PET recording through an intravenous line (Venflon; Becton Dickinson) placed in a cubital vein. The PET data were recorded in list mode and reconstructed using iterative processing and a time-frame structure of 18 · 5, 15 · 10, 4 · 30, 4 · 60, and 10 · 300 s (total, 60 min) and corrected for radioactive decay back to the start of the recording, yielding 3-dimensional images of 128 · 128 · 47 voxels and a central spatial resolution of 6.7 mm (full width at half maximum). The voxel size was 2.4 · 2.4 · 3.1 mm. During both of the PET recordings, arterial blood samples (0.5 mL) were collected manually from the radial artery at 18 · 5, 6 · 10, 3 · 20, 3 · 60, 1 · 120, 1 · 240, 1 · 360, and 4 · 600 s to determine the 18 F-FDGal concentrations (well counter; Packard Instruments). The concentrations were corrected for radioactive decay back to the start of the PET recording (A * , Bq/L blood). During the PET study with no galactose infusion, liver vein blood samples (0.5 mL) were collected at the same time points as the arterial blood samples to determine the 18 F-FDGal concentrations in the liver vein blood (V * , Bq/L blood).
During the PET study with simultaneous galactose infusion (infusion rate, 2.7-5.1 mmol/min; priming dose, 30-45 mmol galactose), the infusion was started 60 min before the PET recording and continued throughout it. In addition to the arterial blood sam- V max /K m 5 intrinsic clearance of galactose; F 5 hepatic blood flow; K syst 5 hepatic systemic clearance of galactose (L blood/min); mean 6 SE 5 weighted mean 6 SE of weighted mean.
Individual values are given as estimate 6 SE of estimate.
ples collected to determine the blood 18 F-FDGal concentrations, 4 arterial blood samples (0.5 mL) were collected during the PET recording at 0, 20, 40, and 60 min for enzymatic determination of the galactose concentration (14) . Good approximation to a constant galactose concentration was achieved in each subject, with no systematic deviation, and the individual mean arterial galactose concentration was used (C A , mmol/L blood). A volume of interest (median size, 300 mL liver tissue; range, 175-600 mL liver tissue) was drawn manually within the liver tissue, 1.5-2 cm from the edge of the liver and avoiding the central part of the organ using the combined PET/CT images. The volume of interest was used to generate a radioactivity concentration time course (kBq/mL liver tissue vs. time). For each PET recording, an individual volume of interest was used.
The hepatic systemic clearance of 18 F-FDGal was determined according to the Gjedde-Patlak representation of data (15, 16) , assuming irreversible metabolism (3). In this relationship, the influx constant of the tracer (K i , L blood/min/L tissue) is given as the asymptote fitted to the linear part of the relationship between the radioactivity concentration time course in the tissue (PET) and the arterial blood samples (quasi-steady-state metabolism). In the present study, the slope was defined using the data measured at 6-20 min after 18 F-FDGal administration, during which time interval the graphical representation of data was linear. The hepatic systemic clearance of 18 F-FDGal from the PET study without galactose infusion was denoted as K * 2gal (L blood/min/L liver tissue) and that from the PET study with galactose infusion was denoted as K * 1gal (L blood/min/L liver tissue). Assuming there is no substantial prehepatic (i.e., splanchnic) 18 F-FDGal metabolism, the mixed portal-arterial liver blood input (dual-input) can be replaced by the single arterial input for calculations of the kinetic parameters of quasi-steady-state metabolism (3). We note that K * 2gal and K * 1gal per definition are systemic clearances. The intrinsic clearance of 18 F-FDGal (V * max =K * m , L blood/min) was calculated using F, A * , and V * measured at quasi-steady-state metabolism during the PET recording without galactose infusion (6-20 min after tracer injection) as (17, 18) :
where E * 5 (A * -V * )/A * is the hepatic extraction fraction of 18 FFDGal, corrected for a mean splanchnic transit time of 1 min (19) to account for nonsteady state as the tracer was administered as a bolus. V * max =K * m was used to calculate the hepatic systemic clearance of 18 F-FDGal for the whole liver (K * syst , L blood/min) as (17) :
The clearance regime of 18 
Hepatic Galactose Kinetics
Galactose (Aarhus University Hospital Pharmacy) was infused at 6 increasing doses (0.7-2.9 mmol/min). Each measurement period was preceded by a 15-to 35-min equilibration period (20) ; a priming dose of galactose (10-20 mmol) (14) . Good approximation to constant galactose concentrations was achieved in each measurement period, and the mean galactose concentrations in the artery (A, mmol/L blood) and liver vein (V, mmol/L blood) were used.
For each subject, the hepatic V max (mmol/min) and the Michaelis constant K m (mmol/L blood) for galactose were estimated according to the sinusoidal perfusion model of in vivo enzymatic elimination (21) 
LC and Hepatic V max of Galactose Measured by Dynamic 18 F-FDGal PET
The LC for 18 F-FDGal was calculated as (3):
that is, the ratio between the intrinsic clearance of 18 F-FDGal, which was calculated from the concentration measurements in blood samples from the artery and liver vein during the 18 F-FDGal PET recording without simultaneous galactose (Eq. 1), and the intrinsic clearance of galactose, which was calculated from blood concentration measurements and Michaelis-Menten kinetics. From the 18 F-FDGal PET recording with simultaneous galactose infusion, the hepatic V max of galactose per volume liver tissue (V PET max , mmol/min/L liver tissue) can be calculated as:
where K Ã 1gal is the hepatic systemic clearance of 18 F-FDGal (L blood/min/L liver tissue), and C A is the mean arterial blood galactose concentration (mmol/L blood) during the PET recording. The ratio (K m 1Ĉ )/Ĉ corrects for the individual approximation to near-saturation of the hepatic galactose elimination. As the present study was performed at near-saturated kinetics, Ĉ was replaced by C A in the calculations.
Statistics
The hepatic systemic clearance of 18 F-FDGal was calculated from linear regression of the PET data using maximum likelihood estimation. The estimation of hepatic galactose V max and K m values included SEs of the estimates of v and Ĉ in the nonlinear regression of the implicit relationship between the variables given by Equation 3 , and the maximum likelihood estimation was used (22, 23) . Individual data are presented as estimate 6 SE of the estimate. The weighted mean values of the individual estimates were calculated using the inverse estimated squared SEs as the weight.
RESULTS
The mean hepatic blood flow was 0.94 L blood/min (range, 0.70-1.76 L blood/min) ( Table 1) , which is comparable to previously published observations using indocyanine green (12, 24) and transit-time ultrasound flow-meter measurements (25) .
Hepatic 18 F-FDGal Kinetics
The PET/CT images showed avid accumulation of 18 FFDGal in the liver tissue compared with other tissues within the PET camera's field of view ( ½Fig: 1 Fig. 1 ). There was no sign of significant splanchnic 18 (Tables 2 and  ½Table 3 3). These results show that galactose and 18 F-FDGal exhibit competitive inhibition for galactokinase and verify that 18 F-FDGal can be used as a PET tracer of hepatic galactose metabolism in humans.
The mean V * max =ðFK * m ) was 0.33, and K * syst (mean, 0.32 L blood/min; range, 0.21-0.44 L blood/min) was accordingly predominantly enzyme-determined. The mean approximation of K * syst to V * max =K * m was 85% (Table 2) . Table 1 summarizes the parameters of the hepatic galactose kinetics. The mean hepatic V max was 2.7 mmol/min, and the mean Michaelis constant K m was 0.95 mmol/L blood, comparable to the mean in vitro K m of 0.97 mmol/L for human liver galactokinase (10, 11) . The estimates of V max and K m were highly correlated within each individual (mean correlation, 93%; range, 81%-99%), and the individual V max / K m ratios were accordingly estimated with high accuracy (22) .
Hepatic Galactose Kinetics
The mean V max /(FK m ) for galactose of 2.5 is comparable to the previously reported finding of 2.6 in healthy humans (24) , and K syst (mean 1.02 L blood/min; range, 0.67-1.21) was predominantly flow-determined. The mean approximation of K syst to F was 92% (Table 1) , which is also comparable to previously reported values (24, 26) .
Correcting the V max of galactose for an assumed liver size of 2% of the body weight (27) and a liver tissue density of 1.07 g/mL liver tissue yielded a mean V max of 1.76 6 0.08 mmol/min/L liver tissue.
LC and Hepatic V max of Galactose Measured by 18 F-FDGal PET Table 3 summarizes the galactose kinetics calculated from the 18 F-FDGal PET/CT data. The LC for 18 F-FDGal was 0.13 6 0.01, which was significantly different from unity (P , 0.01). The mean hepatic V max of galactose (V PET max ) was 1.41 6 0.24 mmol/min/L liver tissue.
DISCUSSION
The aim of the present study was to quantify the regional galactose metabolism in the human liver in vivo using 18 FFDGal PET/CT and to validate the measurements against direct, invasive measurements of hepatic galactose kinetics. Hepatic accumulation of the galactose analog 18 F-FDGal was strongly inhibited by the presence of galactose in the blood, verifying that 18 F-FDGal is metabolized by the same metabolic pathway as galactose in human liver in vivo. The maximum removal rate of galactose in the liver tissue calculated from 18 18 F-FDGal calculated from PET study without galactose infusion; ND 5 not determined (in subject 4, no liver vein blood samples were obtained during PET study); mean 6 SE 5 weighted mean 6 SE of the weighted mean.
mmol/min/L liver tissue, and this result was not significantly different from the value of 1.76 6 0.08 mmol/min/L liver tissue from invasive measurements that were corrected for liver size (P 5 0.60, paired t test). The 18 F-FDGal PET method thus provides an accurate measure of the V max of galactose in liver tissue by external detection. Because the hepatic galactose elimination capacity for the whole liver is predictive of the outcome after liver resection (9), the present method, which enables the estimation of regional hepatic metabolic function, is a promising candidate for preoperative prediction of the remnant liver function after, for example, liver resection for liver tumors. Our LC of 0.13 was significantly different from unity, a result of the high substrate specificity of human galactokinase (10, 11) . Biochemically, the LC is a result of the molecular difference between 18 F-FDGal and galactose, where the hydroxyl group at C-2 in galactose is replaced by 18 F in 18 F-FDGal ( ½Fig: 3 Fig. 3 ). When docked at the active site of galactokinase, the hydroxyl group at C-2 in galactose assists in stabilizing the enzyme-substrate complex through hydrogen bonding to a proximal carboxylate group of an aspartate residue of the enzyme (28) . In 18 F-FDGal, the fluorine atom at C-2 is unable to stabilize the complex to the same extent, and hence, the bonding of the tracer to galactokinase becomes less favorable. In agreement with neither glucokinase nor hexokinase being particularly substrate-specific (29), the in vivo LC for the commonly applied PET tracer of glucose metabolism 18 F-FDG was found to be not significantly different from unity in the pig liver (30) .
In the present study, we determined the individual K m for the hepatic galactose metabolism, enabling us to calculate V PET max (Eq. 5). If the mean K m of 0.95 and the mean LC of 0.13 are considered as population means and the 18 F-FDGal PET/CT study is performed with a galactose infusion ensuring a steady-state C A above 8 mmol/L blood (i.e., C A . 8 times K m ), then the correction for approximation to V max in Equation 5 can be neglected because K * 1gal C A /LC in this case approximates V PET max by more than 85%, which is an acceptable approximation.
An interesting consequence of the different affinities of 18 F-FDGal and galactose for galactokinase resulted in the K * syst being enzyme-determined (on average, it approximated V * max =K * m by 85%), whereas K syst for galactose was predominantly flow-determined. Assuming that the Michaelis constant for a substrate is independent of the maximum removal rate, which is a reasonable assumption, then K * 2gal
provides an indirect measure of the regional V * max without the need for a constant galactose infusion or knowledge of the individual LC. This is a key finding because the LC may change in parenchymal liver disease and it simplifies the setup for 18 F-FDGal PET/CT studies of the regional hepatic metabolic function.
Intrahepatic variation in parenchymal damage is well known in patients with liver diseases (31, 32) , but corresponding changes in hepatic metabolic function have not yet been 18 F-FDGal PET data with galactose infusion (Eq. 5); ND 5 not determined (in subject 4, no liver vein blood samples were obtained during PET study; in subject 5, the PET study with galactose infusion was not performed; mean 6 SE, weighted mean 6 SE of weighted mean.
Individual values are given as estimate 6 SE of estimate. 
CONCLUSION
The study shows that 18 F-FDGal is a substrate for human hepatic galactokinase and that dynamic 18 F-FDGal PET/CT provides an accurate measurement of hepatic galactose metabolism in vivo. The regional V max of galactose that was determined from PET/CT was 1.41 6 0.24 mmol/min/L liver tissue, and this value was validated by direct, invasive measurements of the hepatic galactose kinetics. When the PET/CT study was performed without the galactose infusion, the hepatic systemic clearance of 18 F-FDGal was 0.274 6 0.001 L blood/min/L liver tissue and yielded an indirect measurement of the hepatic V * max for 18 F-FDGal. The 18 F-FDGal PET/CT method enabled studies of the regional variations in hepatic galactokinase activity, which has hitherto not been possible, and the method is likely to prove clinically important for the prediction of remnant liver function in patients undergoing local treatment for liver diseases.
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